• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      PSORIATIC ARTHRITIS

      Once-daily oral treatment for your adult patients with active psoriatic arthritis1

      One dose, one tablet, once a day

      Starting patients on RINVOQ

      A convenient guide providing information on dosing, screening, monitoring and safety recommendations.

      Dosing recommendations1

      • The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without food
      • Tablets should be swallowed whole, and should not be split, crushed, or chewed
      • RINVOQ may be taken at any time of the day; patients may find it easier to take RINVOQ at the same time every day to help them remember to take it

      RINVOQ can be taken as  monotherapy or in combination with methotrexate. In both SELECT-PsA 1 and SELECT PsA-2 studies, consistent responses were observed alone or in combination with methotrexate for primary and key secondary endpoints.1

      Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      UK-UPAD-220089. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com